Combined effects of furanodiene and doxorubicin on the migration and invasion of MDA-MB-231 breast cancer cells in vitro

Zhong,Zhang-Feng; Tan,Wen; Tian,Ke; Yu,Hua; Qiang,Wen-An; Wang,Yi-Tao

doi:10.3892/or.2017.5435

Combined effects of furanodiene and doxorubicin on the migration and invasion of MDA-MB-231 breast cancer cells in vitro

Authors:
- Zhang-Feng Zhong
- Wen Tan
- Ke Tian
- Hua Yu
- Wen-An Qiang
- Yi-Tao Wang
View Affiliations

Affiliations: Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macao SAR 999078, P.R. China, School of Pharmacy, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, P.R. China, Division of Reproductive Science in Medicine, Department of Obstetrics and Gynecology, Feinberg School of Medicine at Northwestern University, Chicago, IL 60611, USA
Published online on: February 10, 2017 https://doi.org/10.3892/or.2017.5435
Pages: 2016-2024

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Furanodiene is one of the major bioactive components isolated from the natural product of the plant, Curcuma wenyujin Y.H. Chen et C. Ling. Furanodiene has been found to exert anticancer effects in various types of cancer cell lines, as well as exhibit antimetastatic activities. However, the antimetastatic capacity of furanodiene in combination with the common chemotherapy drug doxorubicin has not been investigated. We found that doxorubicin at a non-toxic concentration induced cell migration and cell invasion in highly metastatic breast cancer cells. Combinational treatments with furanodiene and doxorubicin blocked the invasion and migration of MDA-MB-231 breast cancer cells in vitro. We also clarified the effects of the combination on the signaling pathways involved in migration, invasion, and cytoskeletal organization. When combined with doxorubicin, furanodiene downregulated the expression of integrin αV and β-catenin and inhibited the phosphorylation of paxillin, Src, focal adhesion kinase (FAK), p85, and Akt. Moreover, combinational treatments also resulted in a decrease in matrix metalloproteinase-9 (MMP-9). Further study demonstrated that the co-treatments with furanodiene did not significantly alter the effects of doxorubicin on the tubulin cytoskeleton, represented by no influence on the expression levels of RhoA, Cdc42, N-WASP, and α/β tubulin. These observations indicate that furanodiene is a potential agent that may be utilized to improve the anticancer efficacy of doxorubicin and overcome the risk of chemotherapy in highly metastatic breast cancer.

View Figures

View References

1	Guthrie D and Gibson AL: Doxorubicin cardiotoxicity: Possible role of digoxin in its prevention. BMJ. 2:1447–1449. 1977. View Article : Google Scholar : PubMed/NCBI
2	Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, Schiff PB, Sorbara L and Zeheb R: Taxol: Mechanisms of action and resistance. Ann NY Acad Sci. 466:733–744. 1986. View Article : Google Scholar : PubMed/NCBI
3	Peterson DE and Sonis ST: Oral complications of cancer chemotherapy: Present status and future studies. Cancer Treat Rep. 66:1251–1256. 1982.PubMed/NCBI
4	Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, et al: Predictive role of HER2/neu, topoisomerase-II-α, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: Results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat. 150:279–288. 2015. View Article : Google Scholar : PubMed/NCBI
5	Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ and Mills E: Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 11:293–303. 2012. View Article : Google Scholar : PubMed/NCBI
6	Lecumberri E, Dupertuis YM, Miralbell R and Pichard C: Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin Nutr. 32:894–903. 2013. View Article : Google Scholar : PubMed/NCBI
7	Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, Li XK and Tang W: Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 4:297–307. 2010.PubMed/NCBI
8	Wang CY, Bai XY and Wang CH: Traditional Chinese medicine: A treasured natural resource of anticancer drug research and development. Am J Chin Med. 42:543–559. 2014. View Article : Google Scholar : PubMed/NCBI
9	Chatterjee K, Zhang J, Honbo N and Karliner JS: Doxorubicin cardiomyopathy. Cardiology. 115:155–162. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K and Sun LZ: Doxorubicin in combination with a small TGFβ inhibitor: A potential novel therapy for metastatic breast cancer in mouse models. PLoS One. 5:e103652010. View Article : Google Scholar : PubMed/NCBI
11	Wang S, Wang L, Chen M and Wang Y: Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression. Chem Biol Interact. 235:76–84. 2015. View Article : Google Scholar : PubMed/NCBI
12	Thandavarayan RA, Giridharan VV, Arumugam S, Suzuki K, Ko KM, Krishnamurthy P, Watanabe K and Konishi T: Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling. PLoS One. 10:e01192142015. View Article : Google Scholar : PubMed/NCBI
13	Ashraf K, Mujeeb M, Ahmad A, Ahmad N and Amir M: Determination of curcuminoids in Curcuma longa Linn. by UPLC/Q-TOF-MS: An application in turmeric cultivation. J Chromatogr Sci. 53:1346–1352. 2015. View Article : Google Scholar : PubMed/NCBI
14	Yang FQ, Wang YT and Li SP: Simultaneous determination of 11 characteristic components in three species of Curcuma rhizomes using pressurized liquid extraction and high-performance liquid chromatography. J Chromatogr A. 1134:226–231. 2006. View Article : Google Scholar : PubMed/NCBI
15	Ray S, Chattopadhyay N, Mitra A, Siddiqi M and Chatterjee A: Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. J Environ Pathol Toxicol Oncol. 22:49–58. 2003.PubMed/NCBI
16	Leu TH, Su SL, Chuang YC and Maa MC: Direct inhibitory effect of curcumin on Src and focal adhesion kinase activity. Biochem Pharmacol. 66:2323–2331. 2003. View Article : Google Scholar : PubMed/NCBI
17	Lin ML, Lu YC, Chen HY, Lee CC, Chung JG and Chen SS: Suppressing the formation of lipid raft-associated Rac1/PI3K/Akt signaling complexes by curcumin inhibits SDF-1α-induced invasion of human esophageal carcinoma cells. Mol Carcinog. 53:360–379. 2014. View Article : Google Scholar : PubMed/NCBI
18	Chen WC, Lai YA, Lin YC, Ma JW, Huang LF, Yang NS, Ho CT, Kuo SC and Way TD: Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. J Agric Food Chem. 61:11817–11824. 2013. View Article : Google Scholar : PubMed/NCBI
19	Hong JH, Lee G and Choi HY: Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts. Korean J Urol. 56:656–665. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhang X, Zhang Y and Li Y: β-elemene decreases cell invasion by upregulating E-cadherin expression in MCF-7 human breast cancer cells. Oncol Rep. 30:745–750. 2013.PubMed/NCBI
21	Shi H, Liu L, Liu LM, Geng J and Chen L: Inhibition of tumor growth by β-elemene through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9 in a murine intraocular melanoma model. Melanoma Res. 25:15–21. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zhong Z, Dang Y, Yuan X, Guo W, Li Y, Tan W, Cui J, Lu J, Zhang Q, Chen X, et al: Furanodiene, a natural product, inhibits breast cancer growth both in vitro and in vivo. Cell Physiol Biochem. 30:778–790. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zhong ZF, Hoi PM, Wu GS, Xu ZT, Tan W, Chen XP, Cui L, Wu T and Wang YT: Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo. J Ethnopharmacol. 141:721–727. 2012. View Article : Google Scholar : PubMed/NCBI
24	Zhong Z, Tan W, Chen X and Wang Y: Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro. Eur J Pharmacol. 737:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
25	Zhong ZF, Li YB, Wang SP, Tan W, Chen XP, Chen MW and Wang YT: Furanodiene enhances tamoxifen-induced growth inhibitory activity of ERa-positive breast cancer cells in a PPARγ independent manner. J Cell Biochem. 113:2643–2651. 2012. View Article : Google Scholar : PubMed/NCBI
26	Li T, Xu XH, Tang ZH, Wang YF, Leung CH, Ma DL, Chen XP, Wang YT, Chen Y and Lu JJ: Platycodin D induces apoptosis and triggers ERK- and JNK-mediated autophagy in human hepatocellular carcinoma BEL-7402 cells. Acta Pharmacol Sin. 36:1503–1513. 2015. View Article : Google Scholar : PubMed/NCBI
27	Zhong Z, Liu LJ, Dong ZQ, Lu L, Wang M, Leung CH, Ma DL and Wang Y: Structure-based discovery of an immunomodulatory inhibitor of TLR1-TLR2 heterodimerization from a natural product-like database. Chem Commun. 51:11178–11181. 2015. View Article : Google Scholar
28	Gao JL, Shi JM, He K, Zhang QW, Li SP, Lee SM and Wang YT: Yanhusuo extract inhibits metastasis of breast cancer cells by modulating mitogen-activated protein kinase signaling pathways. Oncol Rep. 20:819–824. 2008.PubMed/NCBI
29	Saraswati S, Alhaider AA and Agrawal SS: Punarnavine, an alkaloid from Boerhaavia diffusa exhibits anti-angiogenic activity via downregulation of VEGF in vitro and in vivo. Chem Biol Interact. 206:204–213. 2013. View Article : Google Scholar : PubMed/NCBI
30	Miltenburg NC and Boogerd W: Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 40:872–882. 2014. View Article : Google Scholar : PubMed/NCBI
31	Paus R, Haslam IS, Sharov AA and Botchkarev VA: Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 14:e50–e59. 2013. View Article : Google Scholar : PubMed/NCBI
32	Wardill HR, Bowen JM and Gibson RJ: Chemotherapy-induced gut toxicity: Are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol. 70:627–635. 2012. View Article : Google Scholar : PubMed/NCBI
33	Daenen LG, Roodhart JM, van Amersfoort M, Dehnad M, Roessingh W, Ulfman LH, Derksen PW and Voest EE: Chemo-therapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res. 71:6976–6985. 2011. View Article : Google Scholar : PubMed/NCBI
34	Ran S: The role of TLR4 in chemotherapy-driven metastasis. Cancer Res. 75:2405–2410. 2015. View Article : Google Scholar : PubMed/NCBI
35	Park SI, Liao J, Berry JE, Li X, Koh AJ, Michalski ME, Eber MR, Soki FN, Sadler D, Sud S, et al: Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res. 72:2522–2532. 2012. View Article : Google Scholar : PubMed/NCBI
36	Vyas D, Laput G and Vyas AK: Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther. 7:1015–1023. 2014. View Article : Google Scholar : PubMed/NCBI
37	Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, Liu BB, Li QS, Zhang W, Zhu XD, Liu L, et al: Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer. 10:2192010. View Article : Google Scholar : PubMed/NCBI
38	Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML and Arteaga CL: Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest. 117:1305–1313. 2007. View Article : Google Scholar : PubMed/NCBI
39	Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA and Corey SJ: Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer. 101:38–47. 2009. View Article : Google Scholar : PubMed/NCBI
40	Kim S, Harris M and Varner JA: Regulation of integrin α vβ 3-mediated endothelial cell migration and angiogenesis by integrin α5β1 and protein kinase A. J Biol Chem. 275:33920–33928. 2000. View Article : Google Scholar : PubMed/NCBI
41	Parsons JT, Martin KH, Slack JK, Taylor JM and Weed SA: Focal adhesion kinase: A regulator of focal adhesion dynamics and cell movement. Oncogene. 19:5606–5613. 2000. View Article : Google Scholar : PubMed/NCBI
42	Chen HC, Appeddu PA, Isoda H and Guan JL: Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem. 271:26329–26334. 1996. View Article : Google Scholar : PubMed/NCBI
43	Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT and Horwitz AF: FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol. 6:154–161. 2004. View Article : Google Scholar : PubMed/NCBI
44	Thant AA, Nawa A, Kikkawa F, Ichigotani Y, Zhang Y, Sein TT, Amin AR and Hamaguchi M: Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis. 18:423–428. 2000. View Article : Google Scholar : PubMed/NCBI
45	Woodfield RJ, Hodgkin MN, Akhtar N, Morse MA, Fuller KJ, Saqib K, Thompson NT and Wakelam MJ: The p85 subunit of phosphoinositide 3-kinase is associated with β-catenin in the cadherin-based adhesion complex. Biochem J. 360:335–344. 2001. View Article : Google Scholar : PubMed/NCBI
46	Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM and Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:411–422. 1998. View Article : Google Scholar : PubMed/NCBI
47	Bartsch JE, Staren ED and Appert HE: Matrix metalloproteinase expression in breast cancer. J Surg Res. 110:383–392. 2003. View Article : Google Scholar : PubMed/NCBI
48	Van Keymeulen A, Wong K, Knight ZA, Govaerts C, Hahn KM, Shokat KM and Bourne HR: To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J Cell Biol. 174:437–445. 2006. View Article : Google Scholar : PubMed/NCBI
49	Nobes CD and Hall A: Rho, rac and cdc42 GTPases: Regulators of actin structures, cell adhesion and motility. Biochem Soc Trans. 23:456–459. 1995. View Article : Google Scholar : PubMed/NCBI
50	Carlier MF, Ducruix A and Pantaloni D: Signalling to actin: The Cdc42-N-WASP-Arp2/3 connection. Chem Biol. 6:R235–R240. 1999. View Article : Google Scholar : PubMed/NCBI
51	Rohatgi R, Ma L, Miki H, Lopez M, Kirchhausen T, Takenawa T and Kirschner MW: The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell. 97:221–231. 1999. View Article : Google Scholar : PubMed/NCBI
52	Yamazaki D, Kurisu S and Takenawa T: Regulation of cancer cell motility through actin reorganization. Cancer Sci. 96:379–386. 2005. View Article : Google Scholar : PubMed/NCBI
53	Westermann S and Weber K: Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol. 4:938–947. 2003. View Article : Google Scholar : PubMed/NCBI